ERBB2 and breast cancer: Trastuzumab was the first ErbB2-targeting drug to be used in HER + breast cancer, therefore, trastuzumab-associated cardiotoxicity is the most well-studied cardiotoxicity of the cardiotoxicities associated with Erb2-targeting drugs (Herrmann, 2020).